Drugs / Epaglitovirizumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07343791 | Nov 2025 → Nov 2027 expected | colorectal cancer | JIANG LONGWEI | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epaglitovirizumab | “1. Epaglitovirizumab: 5.0 mg/kg, intravenous injection, once every 21 days.” NCT07343791 ↗ |
| Route | Intravenous | “intravenous injection, once every 21 days” NCT07343791 ↗ |